Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

There were no significant differences of other characteristics between two groups.Demographic and clinical characteristics of hemodialysis patientsCharacteristicsOverall(N = 251)Previous(N = 178)New(N = 73)PAge (year)61 ± 1361 ± 1259 ± 150.143Male (%)133(53.0%)92(51.7%)41(56.2%)0.518Dialysis age (month)37.27(3.33,117.32)73.23(34.69,134.17)0< 0.001Primary disease (%)0.173 Glomerulonephritis87(34.7%)63(35.4%)24(32.9%) Diabetes41(16.3%)21(11.8%)20(27.4%) Hypertension39(15.5%)29(16.3%)10(13.7%) Polycystic kidney27(10.8%)20(11.2%)7(9.6%) Other57(22.7%)45(25.3%)12(16.4%)Comorbidity Diabetes mellitus55(21.9%)30(16.9%)15(34.2%)0.002 Cardiovascular disease87(34.7%)61(34.3%)26(35.6%)0.839 History of malignant tumor26(10.4%)19(10.7%)7(9.6%)0.798Laboratory test Serum calcium (mmol/L)2.45 ± 0.152.46 ± 0.152.41 ± 0.170.21 Serum phosphate (mmol/L)1.77 ± 0.381.79 ± 0.371.72 ± 0.400.075 Serum iPTH (pg/ml)309.5 ± 167.8311.9 ± 170.7280.2 ± 134.60.773 ALP (u/L)96.42 ± 71.26100.65 ± 64.4992.11 ± 85.190.181 Hb (g/L)107.78 ± 11.81108.73 ± 11.44105.49 ± 12.430.07 Alb (g/L)39.16 ± 3.3638.85 ± 3.2539.91 ± 3.540.008 PAB (mg/L)292.99 ± 74.15284.97 ± 73.23312.46 ± 73.220.071 hs-CRP (mg/L)4.25 ± 3.194.45 ± 3.564.04 ± 3.130.34 NT-proBNP (pg/ml)5797(3025,16,474)7081(3441,18,204)3744(2631,8483)0.002 nPCR1.13 ± 0.261.13 ± 0.251.12 ± 0.280.672 spKt/V1.44 ± 0.291.46 ± 0.271.41 ± 0.310.169 URR0.70 ± 0.080.70 ± 0.070.69 ± 0.090.29 Total Phosphate-binding capacity88.23 ± 77.7492.23 ± 58.4283.91 ± 80.200.745 Calcitriol (ug/week)0.75(0.00,1.88)0.75(0.00,2.15)0.75(0.00,1.25)0.16 Cinacalcet20(8.0%)17(9.6%)3(4.1%)0.06Values expressed as mean ± SD, median (IQR) or number(percentage); Previous group included patients received hemodialysis treatment before the research; New group included patients new to hemodialysisConversion factors for units: Alb and Hb in g/L to g/dL, ×0.1; calcium in mmol/L to mg/dL, ×4.0; phosphate in mmol/L to mg/dL, ×3.1; iPTH in pg/ml to pmol/L, ×0.11.

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A total of 251 maintenance hemodialysis patients were enrolled.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Higher one-year achievement rate of serum phosphate associated with lower cardiovascular mortality in hemodialysis patients

Study design awaiting verification · BMC Nephrology · 2021

Original publication title

Higher one-year achievement rate of serum phosphate associated with lower cardiovascular mortality in hemodialysis patients

Weichen Zhang; Guoxin Ye; Zhaori Bi; Weisheng Chen; Jing Qian; Minmin Zhang; Ding Ding; Mengjing Wang; Jing Chen

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Keeping one-year achievement rate of serum phosphate higher than 50% provides significant clinical benefits in reducing cardiovascular mortality.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Estimation of phosphate load in hemodialysis patients is always controversial in clinical practice. The aim of this study was to verify individual achievement rate of serum phosphate as the evaluation of phosphate load through investigating its impact on cardiovascular mortality in hemodialysis patients.

Source: Background

Abstract: What methods does the paper describe?

This was a single-center, retrospective cohort study. A total of 251 maintenance hemodialysis patients were enrolled. The individual achievement rate of serum phosphate was defined as the times of tests within the target range divided by total times of tests over a period of time. Cox regression model was used to examine the relationship between individual achievement rate of serum phosphate and cardiovascular mortality.

Source: Methods

Abstract: Results

The mean age of the study population was 61 ± 13 years old. A total of 44 (17.5%) patients died from cardiovascular disease (CVD) during a median follow-up of 65 months. Multivariable Cox analysis showed that one-year serum phosphate achievement rate of 0% (HR = 4.117, P = 0.016) and 25% (HR = 3.343, P = 0.023) increased the risk of cardiovascular mortality while the achievement rate of 50% (HR = 2.129, P = 0.162) and 75% (HR = 1.080, P = 0.902) did not, compared to the rate of 100%.

Urea reduction ratio (URR) was positively, while serum intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), normalized protein catabolic rate (nPCR), and total phosphate-binding capacity of drug were negatively associated with achievement in target of serum phosphate.

Source: Results

Abstract: Conclusions

Keeping one-year achievement rate of serum phosphate higher than 50% provides significant clinical benefits in reducing cardiovascular mortality.

Source: Conclusions
Authors’ abstract

Background

Estimation of phosphate load in hemodialysis patients is always controversial in clinical practice. The aim of this study was to verify individual achievement rate of serum phosphate as the evaluation of phosphate load through investigating its impact on cardiovascular mortality in hemodialysis patients.

Methods

This was a single-center, retrospective cohort study. A total of 251 maintenance hemodialysis patients were enrolled. The individual achievement rate of serum phosphate was defined as the times of tests within the target range divided by total times of tests over a period of time. Cox regression model was used to examine the relationship between individual achievement rate of serum phosphate and cardiovascular mortality.

Results

The mean age of the study population was 61 ± 13 years old. A total of 44 (17.5%) patients died from cardiovascular disease (CVD) during a median follow-up of 65 months. Multivariable Cox analysis showed that one-year serum phosphate achievement rate of 0% (HR = 4.117, P = 0.016) and 25% (HR = 3.343, P = 0.023) increased the risk of cardiovascular mortality while the achievement rate of 50% (HR = 2.129, P = 0.162) and 75% (HR = 1.080, P = 0.902) did not, compared to the rate of 100%.

Urea reduction ratio (URR) was positively, while serum intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), normalized protein catabolic rate (nPCR), and total phosphate-binding capacity of drug were negatively associated with achievement in target of serum phosphate.

Conclusions

Keeping one-year achievement rate of serum phosphate higher than 50% provides significant clinical benefits in reducing cardiovascular mortality.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12882-021-02547-z.

Publication and source details

Original title: Higher one-year achievement rate of serum phosphate associated with lower cardiovascular mortality in hemodialysis patients

Weichen Zhang; Guoxin Ye; Zhaori Bi; Weisheng Chen; Jing Qian; Minmin Zhang; Ding Ding; Mengjing Wang; Jing Chen

BMC Nephrology · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T10:56:40.684916+00:00

DOI: 10.1186/s12882-021-02547-z · PMC8638480